Search results for: hip OA

Amneal Running Out of HCQ Raw Material Due to Finnish Restrictions

Michael Erman & Anne Kauranen | April 10, 2020

NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…

A Collaborative Website as a Communication Model During the COVID-19 Pandemic

Sheryl Mascarenhas, MD, with Greg Stevens, BS | April 10, 2020

Under the onslaught of developing information on COVID-19, one health system found a way to streamline communication using a secure tool it already had access to.

A Transition to 90% Telemedicine: Q&A with Karim Masri, MD

Susan Bernstein | April 9, 2020

How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…

Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

Matthias Blamont & Michael Erman | April 3, 2020

PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…

Inflammation & Psych Issues: A Look at Potential Co-Morbidity

Mike Fillon | March 30, 2020

Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…

ACR Advocates Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments

From the College | March 23, 2020

In partnership with rheumatology and other specialty organizations, the ACR is working against payer and employer policies that mandate specialty pharmacy acquisition of in-office treatments.

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS | March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Texas Society & Meeting Provide Professional Value, Advocacy Vision

Kimberly Retzlaff | March 20, 2020

Hundreds of physicians and practice managers gathered Feb. 28–Mar. 1 in Houston at the annual meeting of the State of Texas Association of Rheumatologists to hear clinical updates, obtain practice management tips and get to know their peers.

The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

Steven M. Harris, Esq. | March 17, 2020

In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

Statins Linked to Reduced Likelihood of Joint Replacement

Reuters Staff | March 16, 2020

NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show. “Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1 Statins have anti-inflammatory effects, and…